OCRA 2027 Rivkin Pilot Grant

OCRA 2027 Rivkin Pilot Grant

Due Date: 03/25/2026

The Ovarian Cancer Research Alliance (OCRA) 2027 Rivkin Pilot Grant provides $75,000 over two years ($37,500/year) to investigators pursuing innovative, early-stage ovarian cancer research that has the potential to generate foundational data for larger studies. Originally offered by the Marsha Rivkin Center for Ovarian Cancer Research in Seattle — a center established by Dr. Saul Rivkin in memory of his wife, Marsha — OCRA took over administration of this grant program after joining forces with the Rivkin Center in April 2025. The Rivkin Pilot Grant is open to investigators across career stages and focuses specifically on ovarian cancer across all biological domains: etiology, prevention, early detection, therapeutics, and cancer biology. The LOI deadline for the 2027 cycle is March 25, 2026. All submissions are through SmartSimple.

Eligibility Criteria:

  • Research must focus specifically on ovarian cancer
  • Open to investigators at all career stages at accredited academic or non-profit research institutions
  • PhD or MD degree required
  • No citizenship or residency restrictions; international applicants welcome
  • PI may hold only one active OCRA grant at a time; only one LOI per grant cycle
  • Applicants are encouraged to contact grants@ocrahope.org with eligibility questions prior to submitting

Funding Details:

  • Award amount: $75,000 total over two years ($37,500/year)
  • Budget should cover direct research expenses in line with OCRA’s current Terms and Conditions
  • 10% indirect costs apply (per OCRA general policy; confirm in current RFA)
  • Full proposal deadline (by invitation): June 10, 2026
  • Award notifications: End of September 2026

Deadline:

  • Letter of Intent (LOI): March 25, 2026
  • LOI notifications (invite to full proposal): Mid-May 2026
  • Full Proposal Deadline (invited only): June 10, 2026
  • Award notifications: End of September 2026
  • All submissions via SmartSimple

Contact / Further Information: